Androgen-Responsive Genes in Prostate Cancer

Preface.- Roles of androgen receptor coregulators and cell signaling in regulation of androgen-responsive genes.- Selective and classical Androgen Response Elements in androgen-regulated gene expression.- Negative androgen-response elements in androgen target genes.- Chromatin looping and long distance regulation by androgen receptor.- The Functionality of Prostate Cancer Predisposition Risk Regions is revealed by AR Enhancers .- Mechanisms of ARE-independent Gene Activation by the Androgen Receptor in Prostate Cancer Cells: potential targets for better intervention strategies.- Androgen action, Wnt signaling, and prostate tumorigenesis.- Toward Revealing the Complexity of Androgen Responsive Protein and Non-coding Transcripts in Prostate Cancer.- Androgen-Responsive Gene Expression in Prostate Cancer Progression.- Androgen receptor regulated genes in prostate cancer initiation vs metastasis.- Androgen-Independent Induction of Androgen-Responsive Genes By Interleukin-6 Regulation.- The effect of AR overexpression on androgen signaling in prostate cancer.- The expression signature of androgen receptor splice variants and their distinctive transcriptional activities in castration-resistant prostate cancer.- Androgen regulation of the cell cycle in prostate cancer.- Androgen Receptor Signaling Interactions Control Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Progression.- Androgen receptor regulation of serum response factor signaling in prostate cancer.- Regulation of angiogenesis by androgen-responsive gene EAF2.- The role of miR-21, an androgen-regulated microRNA, in prostate cancer.- Androgen dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and Clinical Implications.- Clusterin as a target for treatment of castration-resistant prostate cancer.- Index.

The volume editor, Dr. Zhou Wang, is well-noted in the field of prostate cancer and he is theChair for Urological Research at the University of Pittsburgh Medical Center, as well as the co-director of Urological and Prostate Cancer Program at the University of Pittsburgh Cancer Institute.He has also conducted several scientific reviews for several top journals in the area of cancer research.